THE GREATEST GUIDE TO KN 859 PEMBROLIZUMAB

Clinically substantial immune-mediated hematologic adverse reactions (including hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) occurred at an incidence of significantly less than 1% in patients who gained this drug or have been described with using other PD-one/PD-L1 blocking antibodies.The FDA has also approved Keytruda for us